Cargando…

Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption

Detalles Bibliográficos
Autores principales:	Labarga, Pablo, Barreio, Pablo, Sanchez, Carlos A, Medrano, Jose, Vispo, Eugenia, Fernandez, Jose Vicente, Blanco, Francisco, Gonzalez-Lahoz, Juan, Soriano, Vicente
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315913/ http://dx.doi.org/10.1186/1742-4690-7-S1-O13

Ejemplares similares

Efficacy and safety of TDF+FTC+EFV in naïve patients initiating HAART; an observational study comparing Atripla Vs Truvada/Sustiva exposure
por: Sanchez, Carlos Alberto, et al.
Publicado: (2010)

The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
por: Cassetti, I, et al.
Publicado: (2010)

Glomerular filtration (GF) determined by creatinine clearance (CCR) in 24 hours urine and cockcroft & gault (cg) and modification of diet in renal disease (MDRD) equations in a large cohort of HIV+ patients
por: Labarga, Pablo, et al.
Publicado: (2010)

Smoking, female gender and PI use are associated with decreasing renal function in TDF-containing HAART
por: Uglietti, A, et al.
Publicado: (2010)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort
por: van Lunzen, J, et al.
Publicado: (2010)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

2259. Effect of Discontinuation of Tenofovir Disoproxil Fumarate (TDF) on Renal Function in Elderly Veterans
por: Yang, Dylan, et al.
Publicado: (2018)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

HIV/HAART and the brain — what's going on?
por: Portegies, P
Publicado: (2010)

318. Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis of 7 Clinical Trials
por: DeJesus, Edwin, et al.
Publicado: (2019)

A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)
por: Izzo, I, et al.
Publicado: (2010)

2258. Clinical Predictors of Acute Kidney Injury in HIV Infected Patients Treated With Tenofovir Disoproxil Fumarate (TDF)
por: Holleman, Don, et al.
Publicado: (2018)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

Semen may harbor HIV despite effective HAART: another piece in the puzzle
por: Halfon, Philippe, et al.
Publicado: (2010)

A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
por: Gomez, Mario, et al.
Publicado: (2018)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

Evolution of tuberculosis/HIV co-infection in California during the HAART Era, 1996-2007
por: Metcalfe, John, et al.
Publicado: (2010)

Tissue viral dynamics in SIV infected macaques with highly active antiretroviral therapy (HAART)
por: Bourry, Olivier, et al.
Publicado: (2009)

EFICÁCIA E TOXICIDADE DE TENOFOVIR (TDF) E ENTRICITABINA (FTC) PARA INFECÇÕES LEVE A MODERADA PELO SARS-COV-2
por: de Arruda, Erico Antonio Gomes, et al.
Publicado: (2022)

HAART rollout in the new fiscal and economic environment
por: Moatti, J
Publicado: (2012)

Correction to: A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
por: Gomez, Mario, et al.
Publicado: (2018)

Evidence for the roles of oxidative stress, nitrosative stress and Nf-Kb activation in Tenofovir Disoproxil Fumarate (TDF) induced renal damage in rats
por: Ramamoorthy, Hemalatha, et al.
Publicado: (2012)

The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds
por: Pironti, A, et al.
Publicado: (2010)

Risk of death among Italian AIDS cases with AIDS-defining cancers in the post-HAART era
por: Serraino, D, et al.
Publicado: (2009)

Osteoclastic bone resorption directly activates osteoblast function
por: Udagawa, Nobuyuki
Publicado: (2012)

History of HAART – the true story of how effective multi-drug therapy was developed for treatment of HIV disease
por: Delaney, Martin
Publicado: (2006)

Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study
por: Clumeck, Nathan, et al.
Publicado: (2006)

Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design
por: Tibalinda, Prosper, et al.
Publicado: (2016)

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
por: Harris, Marianne, et al.
Publicado: (2017)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
por: Orkin, Chloe, et al.
Publicado: (2020)

Measurements of total and integrated HIV DNA demonstrate sporadic blips of unintegrated HIV DNA in HIV-positive patients on HAART
por: Mexas, A, et al.
Publicado: (2010)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

TDF (Theoretical Domain Framework): how inclusive are TDF domains and constructs compared to other tools for assessing barriers to change?
por: Sarmast, Hamideh, et al.
Publicado: (2014)

Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
por: DeJesus, E, et al.
Publicado: (2010)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hhdtsn5u1851akh3tmlqh85htv